JNJ 61610588

Drug Profile

JNJ 61610588

Alternative Names: JNJ-61610588

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Janssen Research & Development
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Jan 2017 Janssen reinitiates enrolment in a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02671955)
  • 09 Dec 2016 Janssen suspends enrolment in a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT02671955)
  • 01 Jan 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02671955)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top